CNBC's Huckman Previews Key Merck Meeting

Tuesday, 12 Dec 2006 | 8:36 AM ET

Merck is holding its annual analyst meeting today. On this morning’s "Squawk Box", CNBC'S pharmaceuticals reporter Mike Huckman explained why investors are so eager to learn about this company's R & D developments.

Merck Analyst Meeting
Merck holds its annual analyst meeting this morning. Mike Huckman, CNBC Business News Pharmaceuticals Reporter previews the meeting with CNBC's Becky Quick

Huckman says the major issue is whether Pfizer’s loss of torcetrapib, a cholesterol treatment, could be Merck’s gain.

(You might remember, recently Pfizer ended development of torcetrapib after an independent monitoring board recommended that the work end because of an unexpected number of deaths.)

Merck has at least 2 drugs that are in late stage development that appear to raise good cholesterol. If they work well and safely (they could grab what would have been Pfizer's market share) giving Merck a bigger piece of the new “good” cholesterol raising drug market for a longer period of time.

Merck shares have risen to a level that the company has not seen in 2 years.

  Price   Change %Change

  Price   Change %Change


Contact Squawk Box


    Get the best of CNBC in your inbox

    › Learn More
  • Showtimes

    Weekdays 6a ET
    Weekdays 13:00 CET
    Weekdays 18:00 SIN/HK
    Weekdays 20:00 SYD
    New Zealand
    Weekdays 22:00 NZ
  • Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.

  • Becky Quick is co-anchor of "Squawk Box," CNBC's signature morning program. She's also a columnist for Fortune.

  • Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.